5247422025-10-012025-12-315247422025-04-012025-12-315247422025-10-012025-12-31in-capmkt:OtherExpenses1Member5247422025-04-012025-12-31in-capmkt:OtherExpenses1Member5247422025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15247422025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15247422025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15247422025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524742CAPLIPOINTNOTLISTEDINE475E01026CAPLIN POINT LABORATORIES LIMITEDMain BoardEquity2025-04-012026-03-312026-02-052026-01-27INRCroresQuarterlyThird quarterSingle segmentPharmaceutical Formulations2026-02-0511:00:002026-02-0513:00:00Not applicablefalsefalseDefault on loans and debt securities is not applicable.2025-10-012025-12-31UnauditedStandalone18922000003173000002209500000394700000234500000-58000000134100000700000637000002697000001039400000117010000001170100000293500000380000029730000008728000000000872800000-4400000868400000152000000211.4911.460011.4911.461. The above Standalone financial Results for the quarter and Nine Months ended December 31, 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 5, 2026 and reviewed by the Statutory Auditors. <BR> <BR> 2. The Unaudited Standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <BR> <BR> 3. The Company is engaged in the sole activity of carrying on the business of "Pharmaceutical Formulations" and therefore no separate segment reporting is applicable to the Company. <BR> <BR> 4. Other Income and Profit Before Tax includes Dividend from wholly owned subsidiary (Caplin Point Far East Limited): <BR> i) Dividend income of Rs. 23.63 crores was received during the quarter ended 30 September 2025. <BR> ii) For the nine months ended 31 December 2025, dividend income amounted to Rs. 31.75 crores (previous year: Rs. 20.40 crores). <BR> iii) Dividend income for the year ended 31 March 2025 was Rs. 35.53 crores. <BR> <BR> 5. During the quarter and Nine Months ended December 31, 2025, the Company has allotted NIL equity shares of Rs. 2/- each under the Employees Stock Option Schemes and the total number of equity shares of the Company stands at 7,60,11,696 as of December 31, 2025, and 7,60,11,696 as of December 31, 2024. The Company had allotted NIL shares and 69,950 shares during the quarter ended and Nine Month ended December 31, 2024, respectively. <BR> <BR> 6. Pursuant to the notification of the New Labour Codes effective 21st November, 2025 by Government of India whereby multiple existing labour legislations have been consolidated into a unified framework, the Company has assessed the implications of the revised definition of “wages” for employees. The assessment has resulted in an increase in gratuity and compensated absence related employee benefit obligations aggregating to Rs. 0.84 Crores and the impact of the same has been taken in the current quarter results. <BR> The Company continues to monitor developments pertaining to the New Labour Codes, and the impact thereof, if any, will be accounted for in accordance with applicable accounting standards. <BR> <BR> 7. Previous periods' figures have been regrouped / reclassified to be in conformity with current period's classification / disclosure, wherever necessary. <BR> <BR> 2025-04-012025-12-31UnauditedStandalone54697000001229900000669960000011301000005784000002520000034570000015000001853000008483000003114500000358510000003585100000830400000-320000082720000002757900000000027579000006000002758500000152000000236.2836.170036.2836.17Other Expenses269700000Other Expenses848300000Remeasurements of Defined Benefit Plan-5900000-5900000Remeasurements of Defined Benefit Plan800000800000-1500000200000Exchange difference in translating the financial statements of foreign operations00Exchange difference in translating the financial statements of foreign operations0000-4400000600000